TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02953509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13
Study: NCT01118572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM177
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etodolac
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01680952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A) TEST
Description: 1. Extended Release Tacrolimus (Advagraf®)~   ① Living The day before surgery: 0.2 mg/kg(morning dose) po, qd Morning on the day of surgery: 0.1 mg/kg po, qd After surgery, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~   ② Cadaveric Before surgery at once : 0.1 mg/kg within 12hours before surgery. After surgery : 0.2mg/kg po. in the morning After that, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~2. Sirolimus (Rapamune®):~After surgery : 2mg/kg po. within 24hrs after reperfusion. After that, the capacity is adjusted according to the trough level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A) TEST
Description: 1. Extended Release Tacrolimus (Advagraf®)~   ① Living The day before surgery: 0.2 mg/kg(morning dose) po, qd Morning on the day of surgery: 0.1 mg/kg po, qd After surgery, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~   ② Cadaveric Before surgery at once : 0.1 mg/kg within 12hours before surgery. After surgery : 0.2mg/kg po. in the morning After that, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~2. Sirolimus (Rapamune®):~After surgery : 2mg/kg po. within 24hrs after reperfusion. After that, the capacity is adjusted according to the trough level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B) CONTROL
Description: 1. Extended Release Tacrolimus (Advagraf®)~   : Same as above.~2. Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B) CONTROL
Description: 1. Extended Release Tacrolimus (Advagraf®)~   : Same as above.~2. Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid
Study: NCT01358240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Econazole Nitrate Foam 1%
Description: Econazole Nitrate Foam 1% applied once a day for 4 weeks
Study: NCT02953509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
Study: NCT01358240

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam applied once a day for 4 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Econazole Nitrate Cream 1%
Description: Econazole Nitrate Foam 1% applied once a day for 4 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Cream
Description: Placebo cream applied once a day for 4 weeks
Study: NCT00629148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine and Capecitabine
Description: Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine and Capecitabine
Description: Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w
Study: NCT02182154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 ES
Study: NCT02483325

Intervention type: DRUG
Group type: OTHER
Intervention: Allogeneic transplant conditioning
Description: Allogeneic transplant
Study: NCT00817505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1656
Description: Single dose oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1656
Description: Single dose oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1656
Description: Single dose oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1656
Description: Single dose oral suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1656
Description: Single dose oral suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1656
Description: Single dose oral suspension
Study: NCT03679819

Intervention type: DEVICE
Intervention: HR-TRUS
Description: Medical procedures to be performed in the study consist of subject preparation and prostate imaging. The HR-TRUS exam will be done with a transrectal probe either the day before surgery, or in the OR right before surgery. The exam will be done in the same manner as during a regular transrectal ultrasound exam and no invasive procedures will be associated.
Study: NCT02148016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LSCs and amniotic membrane (Modified Technique)
Description: Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic membrane only (Traditional Technique)
Description: Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRK, LSCs, and amniotic membrane (Modified Technique)
Description: Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRK only (Traditional Technique)
Description: PRK alone will be performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Limbal stem cells (LSCs)
Study: NCT04652518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYT-100
Description: oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: LYT-100
Description: oral administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study: NCT01100190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NUVANCE Facial Rejuvenation System
Description: The NUVANCE™ Facial Rejuvenation System is a partially absorbable porous mesh device implant with applicator.
Study: NCT03271099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navigator
Description: Patient Navigation services will be provided to try to eliminate barriers in pursuing survivorship surveillance
Study: NCT01602679

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral micronized progesterone suspension
Description: oral micronized progesterone (100 mg p.o.) suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral micronized progesterone suspension
Description: oral micronized progesterone (100 mg p.o.) suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Study: NCT02018770

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Portable Cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), being 1 905 nm diode (1 mW average power 10 W of peak power, spot of 0.44 cm2), 875 nm diodes 4 (17.5 mW average power for each diode, spot of 1 cm2) and 670 nm diodes 4 (15 mW average power for each diode1 spot, cm2), frequency of 1000 Hz, irradiation time of 300 seconds, energy delivered from 39.3 Joules.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo phototherapy
Description: The volunteers will be subjected to the same Groups ' intervention and placebo pen Phototherapy.
Study: NCT00270621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FHP Night time ENuresis Intervention
Description: Urine alarm/evidence-based psychological Intervention
Study: NCT04615221

Intervention type: OTHER
Group type: OTHER
Intervention: Specimens
Description: Specimens (blood, biopsy, cervical smear, vaginal swab)

Intervention type: OTHER
Group type: OTHER
Intervention: Specimens
Description: Specimens (blood, biopsy, cervical smear, vaginal swab)

Intervention type: OTHER
Group type: OTHER
Intervention: Specimens
Description: Specimens (blood, biopsy, cervical smear, vaginal swab)
Study: NCT03124498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK Cell
Description: Autologous cytokine-induced killer (CIK) cell
Study: NCT02623959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl (IV)
Description: Fentanyl 50 mcg given by vein prior to catheter draining.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl (IV)
Description: Fentanyl 50 mcg given by vein prior to catheter draining.
Study: NCT02933528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS Topical product
Description: once daily for 28 days
Study: NCT02623959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Catheter is drained then Saline placed in the catheter. Catheter is capped for 1 hour and then drained again.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Catheter is drained then Doxycycline 500 mg placed in the catheter. Catheter is capped for 1 hour and then drained again.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone Calls
Description: After the IPC is removed, participant is called one time each month by study staff to check on their status.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: After the IPC is removed, participant is called one time each month by study staff to check on their status.
Study: NCT03294538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Estradiol Vaginal Cream USP, 0.01%
Description: Vaginal cream, generic formulation of the brand product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrace® Vaginal Cream USP, 0.01%
Description: Vaginal cream, brand product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Vaginal Cream
Description: Vaginal cream, placebo. Has no active ingredient
Study: NCT00100165

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth twice a day for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg
Description: 3-(2,4 dimethoxybenzylidene) 150 mg by mouth twice a day for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg
Description: 3-(2,4 dimethoxybenzylidene) 75 mg by mouth twice a day for 4 weeks
Study: NCT01368003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA9090
Description: 200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA9090 with Dutasteride
Description: Dutasteride 3.5 mg orally per day STA9090 200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
Study: NCT03565549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mnemonic
Description: A mnemonic used as a memory aid

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CCHR rule
Description: A list of the CCHR items
Study: NCT00325403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral treprostinil (UT-15C) Sustained Release Tablets
Description: Sustained release oral tablet, twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet twice daily
Study: NCT04511390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transparent, reusable respirator
Description: A novel respirator with dual N95 filter cartridges
Study: NCT05153122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenseGuard
Description: SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals.
Study: NCT01575678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: blinded capsule 2-4 mg/day, oral use, for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: blinded capsule 1/day, oral use, for 4 weeks
Study: NCT04258670

Intervention type: OTHER
Intervention: No intervention
Description: Patients in these cohorts will not be given anti-filariasis therapies because these drugs are not approved for use in patients with high worm burdens (\>20,000 Mf/mL)
Study: NCT00326079

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: implantation of 1 Glaukos iStent versus 2 Glaukos iStents
Study: NCT01689753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEGO connector®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trisodium citrate
Study: NCT04231240

Intervention type: DEVICE
Intervention: Measure of ACT with IStat
Description: Measure of ACT with a point of care device named IStat

Intervention type: DEVICE
Intervention: Measure of ACT with IStat
Description: Measure of ACT with a point of care device named IStat

Intervention type: DEVICE
Intervention: Measure of ACT with IStat
Description: Measure of ACT with a point of care device named IStat

Intervention type: DEVICE
Intervention: Measure of ACT with IStat
Description: Measure of ACT with a point of care device named IStat

Intervention type: DEVICE
Intervention: Measure of ACT with IStat
Description: Measure of ACT with a point of care device named IStat
Study: NCT02857036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rhythmic parameter recording
Description: the following rhythmic parameters are recording during 48 hours: temperature, heart rate and actimetry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rhythmic parameter recording
Description: the following rhythmic parameters are recording during 48 hours: temperature, heart rate and actimetry

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychiatric assessment
Description: different psychometric scales are filled in: Montgomery and Asberg depression rating scale (MADRS), Quick inventory depression scale (QIDS-C16) and Beck depression inventory (BDI)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychiatric assessment
Description: different psychometric scales are filled in: Montgomery and Asberg depression rating scale (MADRS), Quick inventory depression scale (QIDS-C16) and Beck depression inventory (BDI)
Study: NCT01500993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 4 cycles of bolus 5-FU (500 mg/sqm) and 1 cycle of 5-FU based chemoradiotherapy (either 1,000 mg/sqm/day infusional 5-Fu days 1-5 and 29-33 or 225 mg/sqm/day infusional 5-Fu throughout the time of chemoradiotherapy)
Study: NCT03229486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection [Bridion]
Description: Return to T2 point (two contractions) on TOF device is replied by iv 2 mg/kg sugammadex administration, contained in a blinded syringe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine+Glycopyrronium
Description: Return to T2 point (two contractions) on TOF device is replied by iv 0.06 mg/kg neostigmine and 0.005 mg/kg glycopyrrolate administration, contained in a blinded syringe.
Study: NCT03547245

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: eOD-GT8 60mer + AS01B/ DPBS sucrose/IM
Description: 20 μg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: eOD-GT8 60mer + AS01B/ DPBS sucrose/IM
Description: 100 μg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DPBS Sucrose
Description: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DPBS Sucrose
Description: Placebo
Study: NCT02265666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS Tablet FF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIIL 284 BS tablet C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard breakfast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard breakfast
Study: NCT02296892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of sedation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive control arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: For induction and maintenance of sedation
Study: NCT02745639

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: VMAT-SIB
Description: Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and OARs. Patients were treated only if the relative variations of the bone markers between the images were within 3 mm along the three spatial directions. Planning and delivery processes underwent to systematic independent-check procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment. An adequate blood count was necessary to start each chemotherapy infusion. Adjuvant chemotherapy was recommended on patients with high risk factors at pathological examination and decision was left to medical oncologists discretion.
Study: NCT02653209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin - DPP4i
Description: DPP4 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin - SGLT2i
Description: SGLT2 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone - TZD
Description: Thiazolidinedione 30mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
Study: NCT02874599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental restoration
Description: Damaged teeth will be restored